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Podocytes and the actin cytoskeleton as a feasible 
therapeutic target
.Abstract
Podocyte injury is a hallmark of the glomerular disease, which is a direct 
cause of chronic kidney diseases. Importantly, podocyte injury is a conse-
quence of the dysregulation of the actin cytoskeleton. In diverse animal 
models of proteinuric glomerular disease, recovering the integrity of the actin 
structure in podocytes resulted in beneficial effects. In this review, we focus 
on the premise of targeting the actin cytoskeleton as feasible therapeutics for 
treating chronic kidney diseases.
PODOCYTES AND THE MECHANISMS  
OF PROTEINURIA
The selectivity of the glomerular filter is maintained by physical, chemical, and signaling interplay among its three core constituents 
– the glomerular endothelial cells, the glomerular basement membrane 
(GBM), and podocytes (1). Injury to or functional impairment of any of 
these three components of the glomerular filtration barrier can lead to 
proteinuria (2). Podocytes are injured in many forms of human and 
experimental glomerular disease, including minimal change disease, 
focal segmental glomerulosclerosis (FSGS), and diabetes mellitus (3). 
Podocytes are terminally differentiated visceral epithelial cells of the 
glomerulus which develop a characteristic architecture specialized for 
glomerular ultrafiltration. Their structure is traditionally divided into 
three kinds of subcellular compartments: the cell body, microtubule-
driven membrane extensions named primary process, and actin-driven 
membrane extensions named foot processes (FPs). Adjacent podocytes 
are interdigitated with each other at their foot processes, which are sep-
arated from each other by filtration slits and bridged with a specialized 
intercellular junction called a slit diaphragm. The foot processes and slit 
diaphragm serve as an adhesive apparatus to GBM, which together with 
endothelial cells and their glycocalyx form a filtration barrier.
Regardless of the underlying glomerular disease, the early patho-
genic events are characterized by molecular alterations in the slit dia-
phragm without visible morphological changes or more obviously, by a 
reorganization of the FPs structure with fusion of filtration slits termed 
„FP effacement” (3-5). For over 50 years FPs effacement has been a 
cardinal feature of proteinuria. While the mechanistic significance of 
FP effacement with regard to proteinuria has long been a mystery, over 
the last decade numerous studies demonstrated that FP effacement rep-
resents a change in the organization of the actin cytoskeleton (3, 6).
The key findings that unequivocally established the role of the actin 
cytoskeleton in the maintenance of podocyte function were the identi-
fication of distinct genetic mutations that underlie hereditary forms of 
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FSGS in proteins such as nephrin, CD2-associated pro-
tein (CD2AP), a-actinin 4, and inverted formin-2 (INF2) 
(7-11). In addition to distinct mutations, podocyte injury 
could also be multifactorial such as in diabetes or hyper-
tension (12, 13). While mesangial cells were originally 
considered a major cell type in the glomerulus that un-
derlies sclerosis in diabetic nephropathy (DN), this is not 
exclusively true. Both podocytes and endothelial cells, 
and the crosstalk between all three glomerular cell types 
appear to play important roles in the evolution of dia-
betic glomerulosclerosis (14). A comprehensive approach 
to understanding pathologic features by analyzing of all 
three glomerular cell types is currently underway.
ACTIN CYTOSKELETON DYNAMICS  
AS A PHARMACOLOGICAL TARGET  
IN KIDNEY DISEASES
Actin cytoskeleton dynamics are regulated in time and 
space by a large number of signaling, scaffolding, and 
actin-binding proteins – a number of which have been 
linked to chronic kidney diseases (CKD) (6, 15). Given 
the close connection between podocyte structure and 
their function, it has been argued that targeting actin 
cytoskeleton dynamics might be a valuable strategy for 
treating CKD (5, 16, 17). Devising a strategy to directly 
target actin cytoskeleton in podocytes in a beneficial 
manner has been the major challenge.
Rho family GTPases are molecular switches best 
known for their pivotal role in regulation of the actin 
cytoskeleton (18, 19). The prototypic members of this 
family are Cdc42, Rac1, and Rho1. Although distinct, 
they function similarly to the heterotrimeric G proteins 
as they both change their conformations when bound to 
GTP and are switched off when GTP is hydrolyzed. GTP 
binding is facilitated by a GTP exchange factor (GEF), 
and hydrolysis is potentiated by GTPase activating pro-
teins (GAPs). In their GTP bound state, G proteins bind 
and activate a wide variety of downstream effectors. A 
third regulator of small GTPases is called the GDP dis-
sociation inhibitor (GDI) and functions to prevent the 
activation of the GTPase by blocking exchange. Several 
studies identified antagonism between RhoA and Rac1 
GTPases in which activation of RhoA is almost always 
associated with the inactivation of Rac1 and vice versa.
The essential role of those small GTPases in kidney 
filtration was examined by Pawson and colleagues (20). 
Mice lacking Cdc42 in podocytes developed congenital 
nephropathy and died as a result of renal failure within 2 
weeks after birth. In contrast, mice lacking Rac1 and 
RhoA in podocytes were overtly normal and lived to 
adulthood. Kretzler’s group also generated podocyte-
specific deletions of Cdc42 and Rac1, and observed sim-
ilar phenotypes (21). Thus, the absence of Cdc42 resulted 
in congenital nephropathy, whereas the absence of Rac1 
had no effect on the development or the morphology of 
podocytes even after mice were monitored well into adult-
hood. Importantly, the deletion of Rac1 prevented prot-
amine sulfate-induced FP effacement. However, in a 
chronic hypertensive damage model, the absence of Rac1 
worsened proteinuria and sclerosis. This suggests that 
blocking Rac1 can function acutely to prevent FP efface-
ment but after chronic injury, Rac1 is required for repair 
and a return to homeostasis. In complementary studies, 
Shaw and colleagues proposed that Rac1 activation un-
derlies podocyte injury. Expression of Rac1-GAP, Arh-
gap24, was found to be upregulated in podocytes as they 
differentiated both in vitro and in vivo. Mutation in Ar-
hgap24 that impairs its GAP activity, thus resulting in 
increase in the level of Rac1:GTP, was associated with 
FSGS (22). Corroborating those original observations, 
induced expression of constitutively active Rac1 acutely 
caused FP effacement (23), whereas podocyte-specific 
deletion of Rac1 blocked foot process effacement and pro-
teinuria induced by protamine sulfate (21). Together, 
these studies demonstrate that the actin cytoskeleton in 
podocytes is tightly regulated by balancing signaling 
pathways of multiple small GTPases.
Experimental data suggesting that targeting actin cy-
toskeleton in podocytes might be feasible and beneficial 
have been reported recently based on the effect of ROCK 
(Rho-associated protein kinase) inhibitors. ROCK is a 
major downstream effector of RhoA (18, 19), and inhibi-
tors like Fasudil are approved for clinical use outside the 
US to treat pulmonary hypertension by attenuating vas-
cular smooth muscle contraction (24, 25). ROCK in-
hibitors, such as Fasudil, Y27632, SAR407899 and statin, 
have been shown to attenuate proteinuria and interstitial 
fibrosis in many (rodent) models of diabetic nephropathy 
(26, 27), 5/6 nephrectomy (28), nephrotoxic nephritis 
(29), UUO obstruction (30, 31), and ischemia reperfusion 
injury (32). Given such diverse models of kidney injury, 
it is not clear what is the target cell for the ROCK in-
hibitors and exactly how they work. Indeed, therapies that 
lower the blood pressure but that do not involve ROCK 
inhibition such are renin-angiotensin blockers, also show 
efficacy in attenuation of proteinuria (e.g. angiotensin 
converting enzyme (ACE) inhibitors and angiotensin re-
ceptor (AR) blockers) (33), suggesting that podocytes are 
not the direct target of those drugs. That said, use of 
ROCK inhibitors in clinic suggests that targeting actin 
cytoskeleton in a whole organism is a feasible approach.
In addition to the canonical GTPases mentioned 
above, the actin cytoskeleton in podocytes is also regu-
lated by a large GTPase dynamin (34, 35). In contrast to 
small GTPases, dynamin does not require additional 
regulatory proteins such as GAPs, GEFs or GDIs since its 
GTPase cycle is regulated by its oligomerization cycle. 
The structure of the dynamin tetramer that consists of 
two dimers has been recently elucidated (36). Dynamin 
tetramers can oligomerize into partial and full rings or 
helices, and this oligomerization increases its GTPase ac-
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tivity due to the presence of the domain within dynamin 
itself that acts as intramolecular GAP (37). Dynamin has 
a relatively low affinity for both GTP and GDP (38), 
therefore release of GDP does not require presence of des-
ignated GEFs, nor is dynamin: GDP conformation sta-
bilized by the presence of GDIs. A striking feature of 
dynamin assembly into higher order structures is the mul-
titude of interactions in all four molecules (36). Struc-
tural data suggest that these contacts are not necessarily 
static, but characterized by a dynamic equilibrium of dif-
ferent binding conformations. It has been suggested that 
an assembly mode that involves many low-affinity interac-
tions sites facilitates the reversibility of interactions and 
allows for the regulation of dynamin oligomerization, for 
example through nucleotide binding, hydrolysis or phos-
phorylation. Our recent study suggests that dynamin as-
sembly presents an ideal pharmacological target as a proxy 
to target actin cytoskeleton dynamics (39). Another char-
acteristic that distinguishes dynamin from canonical 
small GTPases is that dynamin directly binds actin fila-
ments (10, 40). Dynamin-actin interactions promote 
GTP-dependent dynamin oligomerization, which releas-
es capping protein gelsolin from the barbed ends resulting 
in the potent actin polymerization from the fast growing 
barbed ends and focal adhesion maturation (25). The mo-
lecular mechanism by which dynamin releases gelsolin 
from the barbed ends is at present unknown, but fluores-
cence lifetime imaging microscopy suggests that it re-
quires GTP binding and a major conformational change 
within dynamin tetramers (40). The conformational 
change might be similar to the one suggested for dynamin 
assembly on the lipids (36, 40).
The physiological relevance for dynamin’s role in regu-
lating actin cytoskeleton has been demonstrated when 
mice expressing a dynamin mutant that promotes it to 
oligomerize specifically in podocytes exhibited unusually 
long FPs (39). Experiments using zebrafish further estab-
lished the connection between dynamin-actin interac-
tions, its oligomerization cycle, and function of podocytes 
by demonstrating that the expression of dynamin mutants 
impaired in either actin binding or assembly resulted in 
loss of high molecular weight protein from the circula-
tion. In a complementary approach, administration of the 
small molecule Bis-T-23, which promotes actin-depen-
dent dynamin oligomerization (40), and thus increases 
actin polymerization in injured podocytes, was sufficient 
to improve renal health in diverse models of both tran-
sient and chronic kidney injury. Specifically, Bis-T-23 
restored the normal ultrastructure of foot processes, low-
ered proteinuria, lowered collagen IV deposits in the me-
sangial matrix, diminished mesangial matrix expansion, 
and extended lifespan. These findings for the first time 
showed the feasibility of targeting the actin cytoskeleton 
as therapeutics for CKD. Together, these data further 
underscore alterations in the actin cytoskeleton of kidney 
podocytes as a common hallmark of CKD, which could 
be pharmacologically altered by targeting dynamin oligo-
merization cycle.
Actin dynamics in podocytes are not only regulated by 
GTPases but also by microRNAs (miRNAs) (41). A study 
by Maria Pia Rastaldi and colleagues showed that Brain 
Derived Neurotrophic Factor (BDNF), a member of the 
neurotrophin family of polypeptide growth factors, binds 
the tropomyosin-related kinase B (TrkB) receptor on 
podocytes. BDNF binding resulted in a reduction of mi-
croRNA-134 and an increase in microRNA-132, which 
subsequently increased Limk1 translation and phosphor-
ylation. Increase in Limk1 level increased cofilin phos-
phorylation, thus ultimately increasing the overall actin 
polymerization in podocytes. BDNF treatment pro-
foundly reduced albuminuria in mouse adriamycin ne-
phropathy with accompanied reforming of podocyte FPs. 
Together, the above studies provide compelling evidence 
that regardless of the upstream pathogenic factors that 
initiate podocyte injury (and because of multiple patho-
genic pathways that cause podocyte injury), the actin 
cytoskeleton is a viable target in CKD.
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